Abstract
Objectives: Safety and efficacy data for catheter-based renal denervation (RDN) in the treatment of resistant hypertension have been used to estimate the cost-effectiveness of this approach. However, there are no Dutch-specific analyses. This study examined the cost-effectiveness of RDN from the perspective of the healthcare payer in The Netherlands.
Methods: A previously constructed Markov state-transition model was adapted and updated with costs and utilities relevant to the Dutch setting. The cost-effectiveness of RDN was compared with standard of care (SoC) for patients with resistant hypertension. The efficacy of RDN treatment was modeled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure (SBP).
Results: Treatment with RDN compared to SoC gave an incremental quality-adjusted life year (QALY) gain of 0.89 at an additional cost of €1315 over a patient’s lifetime, resulting in a base case incremental cost-effectiveness ratio (ICER) of €1474. Deterministic and probabilistic sensitivity analyses (PSA) showed that treatment with RDN therapy was cost-effective at conventional willingness-to-pay thresholds (€10,000–80,000/QALY).
Conclusion: RDN is a cost-effective intervention for patients with resistant hypertension in The Netherlands.
Methods: A previously constructed Markov state-transition model was adapted and updated with costs and utilities relevant to the Dutch setting. The cost-effectiveness of RDN was compared with standard of care (SoC) for patients with resistant hypertension. The efficacy of RDN treatment was modeled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure (SBP).
Results: Treatment with RDN compared to SoC gave an incremental quality-adjusted life year (QALY) gain of 0.89 at an additional cost of €1315 over a patient’s lifetime, resulting in a base case incremental cost-effectiveness ratio (ICER) of €1474. Deterministic and probabilistic sensitivity analyses (PSA) showed that treatment with RDN therapy was cost-effective at conventional willingness-to-pay thresholds (€10,000–80,000/QALY).
Conclusion: RDN is a cost-effective intervention for patients with resistant hypertension in The Netherlands.
| Original language | English |
|---|---|
| Pages (from-to) | 76-87 |
| Journal | Journal of medical economics |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2015 |
Keywords
- Cost-effectiveness
- Resistant hypertension
- Renal sympathetic denervation
- Prevention
- Cardiovascular disease
Fingerprint Dive into the research topics of 'Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands'. Together they form a unique fingerprint.
Cite this
Henry, T. L., de Brouwer, B. F. E., van Keep, M. M. L., Blankestijn, P. J., Bots, M. L., & Koffijberg, H. (2015). Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. Journal of medical economics, 18(1), 76-87. https://doi.org/10.3111/13696998.2014.978453